New hope for Tough-to-Treat lung cancer mutation
NCT ID NCT04858958
Summary
This early-stage study is testing a drug called furmonertinib for people with advanced non-small cell lung cancer that has a specific genetic mutation called EGFR exon 20 insertion. The trial will enroll 30 people to see if the drug is safe and can help shrink or control their tumors. It will test two different doses in people who have had prior treatment and one dose in people who have not.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.